touchPODCAST
By touchpodcast
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by touchpodcast
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 541
Description
Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.
Educating physicians on a fully global scale since 2005!
We make positive changes to clinical practice, with the ultimate objective of improving patient and community health.
Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates
Home of:
- touchONCOLOGY
- touchENDOCRINOLOGY
- touchOPHTHALMOLOGY
- touchNEUROLOGY
- touchCARDIOLOGY
- touchINFECTIOUSDISEASES
- touchIMMUNOLOGY
- touchRESPIRATORY
- touchHAEMATOLOGY
- touchDERMATOLOGY
This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
| Episode | Date |
|---|---|
|
The key to ketoacidosis: Unlocking the potential for better DKA monitoring and detection
|
Jul 06, 2026 |
|
Optimizing outcomes in advanced endometrial carcinoma: Navigating guidelines, biomarker-driven immunotherapy and irAE management
|
Jun 15, 2026 |
|
Personalizing cataract surgery: From pre-operative precision to functional vision outcomes
|
May 21, 2026 |
|
Cracking the code of CIDP: Mastering diagnostic precision
|
May 05, 2026 |
|
Looking beyond VEGF to target BRB dysfunction in DME: Novel approaches to prevent vision loss
|
Apr 29, 2026 |
|
Unlocking new potential: Rationale and evidence for dual EZH2/AR inhibition in mCRPC
|
Apr 28, 2026 |
|
Integrating neurosensory pathway insights into modern dry eye management
|
Apr 23, 2026 |
|
Computational pathology in NSCLC: From biomarker discovery to clinical integration
|
Apr 23, 2026 |
|
Shaping the future of PDAC care: Scientific advances and therapeutic innovation
|
Apr 21, 2026 |
|
Exploring all angles: Neuroprotective strategies beyond IOP in primary and steroid-induced open-angle glaucoma
|
Mar 31, 2026 |
|
Optimizing presbyopia-correcting IOL selection and patient expectations
|
Mar 23, 2026 |
|
Advancing outcomes in CP-CML: Guideline-directed approaches to treatment decision-making, monitoring and toxicity management
|
Mar 20, 2026 |
|
The bare necessities of hyperphagia in Prader–Willi syndrome: Expert insights on recognition and management
|
Mar 09, 2026 |
|
Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs
|
Mar 05, 2026 |
|
Evolving paradigms in PNH management: Interpreting the latest data
|
Feb 25, 2026 |
|
Diagnosis, multidisciplinary monitoring and individualized management in LOPD
|
Jan 21, 2026 |
|
Unlocking the possibilities of BCMA-directed therapies in RRMM: Latest perspectives from IMS and ASH 2025
|
Jan 21, 2026 |
|
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
|
Jan 15, 2026 |
|
Evolving strategies in low-grade serous ovarian cancer: Applying the evidence to optimize patient care
|
Jan 15, 2026 |
|
Managing cytopenias: The path to transfusion independence for patients with myelofibrosis
|
Dec 05, 2025 |
|
Innovations and advances in CML: Focus on navigating early-line options and maintaining quality of life
|
Nov 20, 2025 |
|
Breakthroughs in treating NSCLC: Targeting KRAS
|
Nov 19, 2025 |
|
HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers
|
Nov 18, 2025 |
|
Delivering state-of-the-art care for GEP-NETs: Evidence-based strategies for PRRT
|
Nov 18, 2025 |
|
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
|
Nov 17, 2025 |
|
Eyeing better outcomes in diabetic macular oedema: Clinical insights on the evolving role of corticosteroids
|
Oct 30, 2025 |
|
Diagnosis and treatment of patients with Lennox–Gastaut syndrome
|
Oct 23, 2025 |
|
Updates in hypertrophic cardiomyopathy care: Bridging the current treatment gaps with emerging novel therapies
|
Oct 20, 2025 |
|
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
|
Oct 20, 2025 |
|
Staying ahead of the curve in HNSCC care: Refining the role of immunotherapy across disease stages
|
Oct 09, 2025 |
|
FCS unmasked: Closing gaps in diagnosis, treatment and patient support
|
Oct 02, 2025 |
|
Achieving effective lifespan care in sickle cell disease: From recognizing the burden to novel therapeutics
|
Oct 01, 2025 |
|
Bridging diagnostic and therapeutic gaps in Fabry disease management
|
Sep 30, 2025 |
|
Applying patient and disease characteristics to guide R/M NPC treatment
|
Sep 24, 2025 |
|
Therapeutic advances in RRMM: What is the latest on practical application of BCMA-directed therapies?
|
Sep 10, 2025 |
|
Phacoemulsification in cataract surgery: Evolving options to optimize refractive outcomes
|
Sep 10, 2025 |
|
Stargardt disease: Improving awareness, diagnosis and patient support
|
Aug 27, 2025 |
|
Mastering DKA management: From pathophysiology to prevention and ketone monitoring strategies
|
Aug 26, 2025 |
|
A case-based discussion on PAH: Optimizing early detection, risk stratification and treatment decision-making
|
Aug 21, 2025 |
|
Continuous glucose monitoring for cardiovascular risk reduction: The next frontier in preventive care
|
Aug 20, 2025 |
|
HER2 as a targetable biomarker in gastrointestinal oncology
|
Aug 19, 2025 |
|
Navigating the evolving role of immunotherapy in advanced endometrial carcinoma
|
Jul 31, 2025 |
|
Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease
|
Jul 29, 2025 |
|
Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025
|
Jul 09, 2025 |
|
Advancing care for patients with infantile haemangiomas: Timing is key
|
Jul 07, 2025 |
|
Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist
|
Jun 26, 2025 |
|
Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease
|
Jun 25, 2025 |
|
Applying immunotherapy in clinical practice for patients with early-stage NSCLC
|
Jun 23, 2025 |
|
Applying immunotherapy in clinical practice for patients with early-stage NSCLC
|
Jun 23, 2025 |
|
Towards personalized care for people living with HIV: Supporting open dialogue and informed treatment choices
|
Jun 19, 2025 |
|
RET-positive NSCLC: Translating insights into targeted approaches
|
May 15, 2025 |
|
RET-positive NSCLC: Translating insights into targeted approaches
|
May 15, 2025 |
|
Advances in dry eye disease: From diagnosis to new treatment targets
|
May 08, 2025 |
|
Recent advances in the care of patients with geographic atrophy: Bringing new and emerging therapies into focus
|
May 06, 2025 |
|
The potential of BTKi therapies in delaying MS progression
|
Apr 30, 2025 |
|
Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors
|
Apr 30, 2025 |
|
MDT perspectives on why and how to implement continuous glucose monitoring in T2D
|
Apr 30, 2025 |
|
MDT perspectives on evolving options for insulin therapy
|
Apr 30, 2025 |
|
MDT perspectives on understanding clinical inertia in T2D
|
Apr 30, 2025 |
|
Navigating the clinical impact of TROP2-targeting in NSCLC
|
Apr 24, 2025 |
|
Navigating the clinical impact of TROP2-targeting in NSCLC
|
Apr 24, 2025 |
|
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchNEUROLOGY
|
Apr 11, 2025 |
|
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchENDOCRINOLOGY
|
Apr 11, 2025 |
|
The evolving standard of care for advanced/recurrent endometrial cancer: A practice-focused discussion of immunotherapy
|
Apr 07, 2025 |
|
Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia
|
Apr 02, 2025 |
|
Video 3: MDT perspectives on identifying and managing key ADC treatment toxicities in patients with metastatic breast cancer
|
Mar 31, 2025 |
|
Video 2: MDT perspectives on communicating ADC treatment toxicities to patients with metastatic breast cancer
|
Mar 31, 2025 |
|
Video 1: MDT perspectives on the safety profiles of current and emerging ADCs in metastatic breast cancer
|
Mar 31, 2025 |
|
Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease
|
Mar 31, 2025 |
|
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
|
Mar 18, 2025 |
|
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
|
Mar 18, 2025 |
|
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
|
Mar 18, 2025 |
|
Expanding horizons for patients with Pompe disease Using data to guide clinical practice
|
Mar 18, 2025 |
|
MDT perspectives on the importance of patient engagement in PARPi use - Video 3
|
Mar 06, 2025 |
|
MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2
|
Mar 06, 2025 |
|
MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1
|
Mar 06, 2025 |
|
The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY
|
Feb 27, 2025 |
|
The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO
|
Feb 27, 2025 |
|
From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer
|
Feb 21, 2025 |
|
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals
|
Feb 20, 2025 |
|
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals
|
Feb 20, 2025 |
|
Looking to the future in the treatment of steroid-refractory chronic GvHD
|
Feb 18, 2025 |
|
Looking to the future in the treatment of steroid-refractory chronic GvHD
|
Feb 18, 2025 |
|
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024
|
Feb 06, 2025 |
|
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024
|
Feb 06, 2025 |
|
RAS mutations and personalized cancer care: Targeting the future
|
Jan 30, 2025 |
|
What’s new in primary ITP? Key updates from ASH 2024
|
Jan 29, 2025 |
|
What’s new in primary ITP? Key updates from ASH 2024
|
Jan 29, 2025 |
|
Focused insights: Data implications of ADCs in NSCLC treatment
|
Jan 24, 2025 |
|
Focused insights: Data implications of ADCs in NSCLC treatment
|
Jan 24, 2025 |
|
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGY
|
Jan 21, 2025 |
|
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchHAEMATOLOGY
|
Jan 21, 2025 |
|
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY
|
Jan 06, 2025 |
|
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY
|
Jan 06, 2025 |
|
Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting
|
Dec 19, 2024 |
|
Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY
|
Dec 17, 2024 |
|
Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY
|
Dec 17, 2024 |
|
Advances in IOL technology and power calculations: Updates and innovations from 2024
|
Dec 04, 2024 |
|
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
|
Nov 27, 2024 |
|
Primary biliary cholangitis: Appraising the changing therapeutic landscape
|
Nov 14, 2024 |
|
Primary biliary cholangitis: Appraising the changing therapeutic landscape
|
Nov 14, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
|
Nov 14, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
|
Nov 14, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
|
Nov 14, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
|
Nov 14, 2024 |
|
touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
|
Nov 13, 2024 |
|
touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
|
Nov 13, 2024 |
|
touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
|
Nov 13, 2024 |
|
touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
|
Nov 13, 2024 |
|
touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
|
Nov 13, 2024 |
|
touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
|
Nov 13, 2024 |
|
Vaccination strategies for pneumococcal disease
|
Nov 05, 2024 |
|
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
|
Oct 28, 2024 |
|
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
|
Oct 28, 2024 |
|
Pharmacological management of agitation in Alzheimer's dementia
|
Oct 24, 2024 |
|
touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORY
|
Oct 24, 2024 |
|
touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIO
|
Oct 24, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1
|
Oct 16, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2
|
Oct 16, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1
|
Oct 16, 2024 |
|
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2
|
Oct 16, 2024 |
|
Targets in early NSCLC: A focus on EGFR-mutant treatment options
|
Oct 15, 2024 |
|
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
|
Oct 07, 2024 |
|
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
|
Oct 07, 2024 |
|
Innovations in glaucoma care: Targeting pathophysiology to expand treatment options
|
Oct 07, 2024 |
|
Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents
|
Sep 30, 2024 |
|
Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents
|
Sep 30, 2024 |
|
Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors
|
Sep 26, 2024 |
|
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchIMMUNOLOGY
|
Sep 26, 2024 |
|
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchIMMUNOLOGY
|
Sep 26, 2024 |
|
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchIMMUNOLOGY
|
Sep 26, 2024 |
|
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchDERMATOLOGY
|
Sep 26, 2024 |
|
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchDERMATOLOGY
|
Sep 26, 2024 |
|
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchDERMATOLOGY
|
Sep 26, 2024 |
|
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchENDOCRINOLOGY
|
Sep 26, 2024 |
|
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchENDOCRINOLOGY
|
Sep 26, 2024 |
|
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchENDOCRINOLOGY
|
Sep 26, 2024 |
|
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease - touchRESPIRATORY
|
Sep 25, 2024 |
|
Perspectives on EGFR-mutant and wildtype NSCLC Tailoring treatment advances in late-stage disease - touchONCOLOGY
|
Sep 25, 2024 |
|
Expanding HER2 horizons: Implications for NSCLC and beyond
|
Sep 25, 2024 |
|
Expanding HER2 horizons: Implications for NSCLC and beyond
|
Sep 25, 2024 |
|
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
|
Sep 05, 2024 |
|
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
|
Sep 05, 2024 |
|
Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes
|
Aug 29, 2024 |
|
Personalizing care within the MDT for patients with early through to advanced RCC
|
Aug 19, 2024 |
|
Selecting ART: Working with people living with HIV to find the best regimen
|
Aug 15, 2024 |
|
Thyroid eye disease: An evolving continuum of care
|
Aug 08, 2024 |
|
Thyroid eye disease: An evolving continuum of care
|
Aug 08, 2024 |
|
Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies
|
Aug 05, 2024 |
|
Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies
|
Aug 05, 2024 |
|
Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
|
Aug 02, 2024 |
|
The path from detection to personalized long-term care for Fabry disease
|
Jul 31, 2024 |
|
The path from detection to personalized long-term care for Fabry disease
|
Jul 31, 2024 |
|
The path from detection to personalized long-term care for Fabry disease
|
Jul 31, 2024 |
|
Demystifying virology: The link between the HIV life cycle and ART
|
Jul 31, 2024 |
|
Knowledge for nurses ADC updates in breast cancer
|
Jul 30, 2024 |
|
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma
|
Jul 26, 2024 |
|
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma
|
Jul 26, 2024 |
|
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
|
Jul 24, 2024 |
|
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
|
Jul 24, 2024 |
|
Early diagnosis and treatment of NMOSD: Practical insights
|
Jul 19, 2024 |
|
Early diagnosis and treatment of NMOSD: Practical insights
|
Jul 19, 2024 |
|
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 1 touchHAEMATOLOGY
|
Jul 17, 2024 |
|
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 2 touchHAEMATOLOGY
|
Jul 17, 2024 |
|
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 3 touchHAEMATOLOGY
|
Jul 17, 2024 |
|
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 4 touchHAEMATOLOGY
|
Jul 17, 2024 |
|
Recognizing and managing HLH in the critical care setting Best practice for the multidisciplinary team - Part 1 touchIMMUNOLOGY
|
Jul 17, 2024 |
|
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 2 touchIMMUNOLOGY
|
Jul 17, 2024 |
|
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 3 touchIMMUNOLOGY
|
Jul 17, 2024 |
|
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 4 touchIMMUNOLOGY
|
Jul 17, 2024 |
|
Let’s talk about agitation in Alzheimer’s dementia: Prevalence, behavioural symptoms and reaching a diagnosis
|
Jul 16, 2024 |
|
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
|
Jul 16, 2024 |
|
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
|
Jul 16, 2024 |
|
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
|
Jul 16, 2024 |
|
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
|
Jul 16, 2024 |
|
Immunotherapy for early-stage, resectable NSCLC
|
Jul 10, 2024 |
|
Immunotherapy for early-stage, resectable NSCLC
|
Jul 10, 2024 |
|
Impact of pharmacotherapies for achondroplasia – Discussion 4 / 4
|
Jun 19, 2024 |
|
Monitoring and early treatment initiation - Discussion 3
|
Jun 19, 2024 |
|
Early recognition of achondroplasia – Discussion 2 / 4
|
Jun 19, 2024 |
|
MDT management of achondroplasia – Discussion 1 / 4
|
Jun 19, 2024 |
|
Advanced urothelial carcinoma: Expert guidance to navigate an evolving therapeutic landscape
|
Jun 17, 2024 |
|
Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer
|
May 31, 2024 |
|
Optimizing management of bronchiolitis obliterans syndrome: Current strategies, future directions
|
May 21, 2024 |
|
Optimizing management of bronchiolitis obliterans syndrome: Current strategies, future directions
|
May 17, 2024 |
|
Gastrointestinal oncology experts discuss precision medicine in the treatment of colorectal cancer
|
Apr 23, 2024 |
|
Current treatments and unmet needs in limited-stage small cell lung cancer
|
Apr 16, 2024 |
|
Current treatments and unmet needs in limited-stage small cell lung cancer
|
Apr 16, 2024 |
|
How to recognize and diagnose agitation in Alzheimer’s dementia – Discussion 5
|
Mar 28, 2024 |
|
Understanding agitation in Alzheimer’s dementia – Discussion 4
|
Mar 28, 2024 |
|
Managing agitation in Alzheimer’s dementia – Discussion 3
|
Mar 28, 2024 |
|
How to recognize and diagnose agitation in Alzheimer’s dementia – Discussion 2
|
Mar 28, 2024 |
|
Understanding agitation in Alzheimer’s dementia – Discussion 1
|
Mar 28, 2024 |
|
Experts in diabetes discuss the latest developments in basal insulin therapy for type 2 diabetes management
|
Mar 28, 2024 |
|
What’s on the horizon to tackle unmet needs in recurrent metastatic SCCHN?
|
Feb 28, 2024 |
|
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
|
Feb 22, 2024 |
|
Expert insights in food allergy: Considerations for diagnosis and management in primary care and beyond
|
Feb 21, 2024 |
|
Expert insights in food allergy: Considerations for diagnosis and management in primary care and beyond
|
Feb 21, 2024 |
|
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
|
Feb 21, 2024 |
|
Addressing the diagnosis and management of pet allergies in primary care and beyond
|
Feb 14, 2024 |
|
Addressing the diagnosis and management of pet allergies in primary care and beyond
|
Feb 09, 2024 |
|
The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
|
Feb 09, 2024 |
|
The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
|
Feb 09, 2024 |
|
Diagnosing and treating patients with EoE: Tackling the difficulties
|
Feb 07, 2024 |
|
Diagnosing and treating patients with EoE: Tackling the difficulties
|
Feb 07, 2024 |
|
touchMDT – Patient-centric care for prurigo nodularis – Discussion 3
|
Feb 06, 2024 |
|
touchMDT – Management of prurigo nodularis – Discussion 2
|
Feb 06, 2024 |
|
touchMDT – Burden of prurigo nodularis – Discussion 1
|
Feb 06, 2024 |
|
touchMDT – Patient-centric care for prurigo nodularis – Discussion 3
|
Feb 06, 2024 |
|
touchMDT – Management of prurigo nodularis – Discussion 2
|
Feb 06, 2024 |
|
touchMDT – Burden of prurigo nodularis – Discussion 1
|
Feb 06, 2024 |
|
Is HER2 targeting on the horizon for urothelial carcinoma?
|
Jan 24, 2024 |
|
Addressing challenges in diagnosis and treatment of IgG4-related gastrointestinal disease
|
Jan 24, 2024 |
|
Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL
|
Jan 10, 2024 |
|
Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL
|
Jan 10, 2024 |
|
Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
|
Jan 09, 2024 |
|
Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
|
Jan 09, 2024 |
|
Haemato-oncology experts discuss managing the practicalities of CAR T-cell therapy in relapsed or refractory follicular lymphoma
|
Jan 08, 2024 |
|
Haemato-oncology experts discuss managing the practicalities of CAR T-cell therapy in relapsed or refractory follicular lymphoma
|
Jan 08, 2024 |
|
Advances in IOL technology and power calculations: Updates and innovations
|
Dec 22, 2023 |
|
Guideline-based treatment of recurrent/metastatic cervical cancer
|
Dec 13, 2023 |
|
IgG4-related disease: How to identify, diagnose and treat
|
Dec 11, 2023 |
|
Paediatric atopic dermatitis: Evolving strategies for improved management
|
Dec 07, 2023 |
|
Paediatric atopic dermatitis: Evolving strategies for improved management
|
Dec 07, 2023 |
|
Optimizing the management of patients with relapsing forms of MS: An update on emerging treatment options
|
Dec 06, 2023 |
|
Cataract surgery and ocular comorbidities: Key considerations for intraocular lens choice
|
Dec 04, 2023 |
|
PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
|
Nov 27, 2023 |
|
Clinical care pathway for Alzheimer’s disease Driving improvements in diagnosis
|
Nov 17, 2023 |
|
Using anti-CGRP antibodies for migraine prevention: Key learnings
|
Oct 30, 2023 |
|
Treatment of endometrial cancer: Highlights from ESGO 2023
|
Oct 19, 2023 |
|
Practical considerations for personalized medicine in thyroid cancer: Which therapies are suited to particular patient profiles?
|
Oct 19, 2023 |
|
Practical considerations for personalized medicine in thyroid cancer: Which therapies are suited to particular patient profiles?
|
Oct 19, 2023 |
|
Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations
|
Oct 05, 2023 |
|
Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations
|
Oct 05, 2023 |
|
COVID-19 vaccination: What have we learned and what more can we do to address vaccine inequity in the Middle East?
|
Oct 04, 2023 |
|
COVID-19 vaccination: What have we learned and what more can we do to address vaccine inequity in Africa?
|
Oct 04, 2023 |
|
The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections
|
Sep 21, 2023 |
|
The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections
|
Sep 21, 2023 |
|
Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
|
Sep 14, 2023 |
|
Optimizing IOL selection Focus on IOL calculations in “difficult” eyes
|
Sep 11, 2023 |
|
Anti-CGRP antibody preventive treatment of migraine: Practical management
|
Aug 30, 2023 |
|
The complement system in NMOSD and MG: A target for therapeutic benefit?
|
Aug 15, 2023 |
|
The complement system in NMOSD and MG: A target for therapeutic benefit?
|
Aug 15, 2023 |
|
The complement system in NMOSD and MG: A target for therapeutic benefit
|
Aug 15, 2023 |
|
Contemporary insights on sickle cell disease complications and recent advances in therapy
|
Aug 15, 2023 |
|
Contemporary insights on sickle cell disease complications and recent advances in therapy
|
Aug 15, 2023 |
|
Contemporary insights on sickle cell disease complications and recent advances in therapy
|
Aug 15, 2023 |
|
Contemporary insights on sickle cell disease complications and recent advances in therapy
|
Aug 14, 2023 |
|
New and emerging agents in HER2-negative metastatic breast cancer Implications for current and future practice
|
Aug 14, 2023 |
|
DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchCARDIOLOGY
|
Aug 10, 2023 |
|
DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchNEUROLOGY
|
Aug 10, 2023 |
|
Key considerations in the management of irAEs with ICIs in advanced or recurrent endometrial cancer
|
Aug 09, 2023 |
|
Importance of shared decision making in the management of endometrial cancer
|
Aug 09, 2023 |
|
Improving outcomes with ICIs in advanced or recurrent endometrial cancer
|
Aug 09, 2023 |
|
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic - touchHAEMATOLOGY
|
Jul 31, 2023 |
|
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic - touchONCOLOGY
|
Jul 31, 2023 |
|
Preventing HPV-associated cancer by maximizing vaccine uptake
|
Jul 31, 2023 |
|
Preventing HPV-associated cancer by maximizing vaccine uptake
|
Jul 31, 2023 |
|
Fulfilling the potential of HER2-targeting in colorectal cancer
|
Jul 26, 2023 |
|
Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies - Modules 1 & 2
|
Jul 20, 2023 |
|
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
|
Jul 18, 2023 |
|
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
|
Jul 18, 2023 |
|
Current and future considerations for the use of immune checkpoint inhibitors in NSCLC
|
Jul 10, 2023 |
|
Current and future considerations for the use of immune checkpoint inhibitors in NSCLC
|
Jul 10, 2023 |
|
Shaping ART around individual needs: Maximizing adherence and quality of life
|
Jun 29, 2023 |
|
Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care
|
Jun 22, 2023 |
|
Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care
|
Jun 22, 2023 |
|
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
|
Jun 21, 2023 |
|
Key considerations for treatment selection and sequencing in patients with RRMM Lessons from real-life clinical practice
|
Jun 21, 2023 |
|
Individualizing long-term treatment and care in active MS
|
Jun 12, 2023 |
|
MDT perspectives on approaches for the use of immune checkpoint inhibitor therapy in patients with solid tumours
|
Jun 08, 2023 |
|
MDT perspectives on the role of biomarkers in informing immune checkpoint inhibitor use across tumour types
|
Jun 08, 2023 |
|
MDT perspectives on strategies for identifying and monitoring immune-related adverse events
|
Jun 08, 2023 |
|
MDT perspectives on indications for immune checkpoint inhibitors in patients with solid tumours
|
Jun 08, 2023 |
|
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
|
May 31, 2023 |
|
Experts in infectious diseases discuss the practical considerations for COVID-19 vaccination in the Middle East
|
May 30, 2023 |
|
Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
|
May 18, 2023 |
|
Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
|
May 18, 2023 |
|
Experts in infectious diseases discuss the practical considerations for COVID-19 vaccination in Africa
|
May 11, 2023 |
|
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
|
May 04, 2023 |
|
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
|
May 04, 2023 |
|
Clinical updates from SGO 2023 on PARP inhibitors in ovarian cancer
|
May 03, 2023 |
|
Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach
|
Apr 24, 2023 |
|
Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach
|
Apr 24, 2023 |
|
ICI-based combinations for advanced/metastatic renal cell carcinoma: Highlights from ASCO GU 2023
|
Apr 24, 2023 |
|
Blood-based biomarkers: Supporting the diagnosis and treatment of Alzheimer’s disease
|
Apr 21, 2023 |
|
Reducing transmission of COVID-19 Spotlight on vaccines
|
Apr 20, 2023 |
|
Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer: Current status and future perspectives
|
Apr 17, 2023 |
|
Optimizing strategies for the treatment of colorectal cancer in the biomarker era - Modules 1 & 2
|
Apr 17, 2023 |
|
Improving outcomes of immune-related adverse events: The crucial role of the pharmacist
|
Apr 11, 2023 |
|
Managing Cushing’s disease and goals of medical therapy
|
Mar 30, 2023 |
|
Treatment pathways with a focus on medical therapies for Cushing’s disease
|
Mar 30, 2023 |
|
Optimizing patient outcomes in Cushing’s disease
|
Mar 30, 2023 |
|
Optimizing strategies for the treatment of colorectal cancer in the biomarker era - Module 1
|
Mar 28, 2023 |
|
MDT perspectives on novel approaches to overcome resistance with standard-of-care immunotherapy for non-driver mutation metastatic NSCLC
|
Mar 27, 2023 |
|
MDT perspectives on tracking prognostic and predictive biomarkers for immunotherapy
|
Mar 27, 2023 |
|
MDT and patient perspectives on shared decision making for emerging treatment options
|
Mar 27, 2023 |
|
MDT perspectives on the limitations of standard of care immunotherapy for non-driver mutation metastatic NSCLC
|
Mar 27, 2023 |
|
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
|
Mar 24, 2023 |
|
Key considerations for the clinical management of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
|
Mar 23, 2023 |
|
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
|
Mar 21, 2023 |
|
MDT and patient advocate perspectives on the key signs and symptoms of DMD
|
Mar 14, 2023 |
|
MDT and patient advocate perspectives on diagnosing DMD and how to screen
|
Mar 14, 2023 |
|
MDT perspectives on established methods for managing DMD
|
Mar 14, 2023 |
|
MDT perspectives on novel pharmacological and gene therapies for patients with DMD
|
Mar 14, 2023 |
|
Understanding the pathophysiology of multiple sclerosis and the development of new therapies
|
Mar 13, 2023 |
|
Understanding the pathophysiology of multiple sclerosis and the development of new therapies
|
Mar 13, 2023 |
|
Emerging data with immunotherapy in ESCC and potential impact for clinical practice
|
Mar 09, 2023 |
|
Improving the alpha-mannosidosis patient journey
|
Feb 23, 2023 |
|
Improving the alpha-mannosidosis patient journey
|
Feb 23, 2023 |
|
Improving the alpha-mannosidosis patient journey
|
Feb 23, 2023 |
|
HER2 testing in colorectal cancer
|
Feb 23, 2023 |
|
Managing treatment side effects in HER2-positive colorectal cancer
|
Feb 23, 2023 |
|
Supporting patients with HER2-positive colorectal cancer
|
Feb 23, 2023 |
|
Utilizing HER2-targeted treatments in colorectal cancer
|
Feb 23, 2023 |
|
Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates
|
Feb 20, 2023 |
|
Higher-risk MDS: An update on emerging novel agents
|
Feb 14, 2023 |
|
Supporting families to optimize outcomes
|
Feb 13, 2023 |
|
Supporting families to optimize outcomes
|
Feb 13, 2023 |
|
The role of the MDT in managing paediatric severe type 2 asthma
|
Feb 13, 2023 |
|
The role of the MDT in managing paediatric severe type 2 asthma
|
Feb 13, 2023 |
|
The use of biologics in children with severe type 2 asthma
|
Feb 13, 2023 |
|
The use of biologics in children with severe type 2 asthma
|
Feb 13, 2023 |
|
Accurately diagnosing severe type 2 asthma in children
|
Feb 13, 2023 |
|
Accurately diagnosing severe type 2 asthma in children
|
Feb 13, 2023 |
|
MDT perspectives on the current and emerging second-line treatment options for SCLC
|
Jan 19, 2023 |
|
MDT perspectives on managing side effects associated with second-line treatment for SCLC
|
Jan 19, 2023 |
|
MDT perspectives on tailoring second-line treatment selection to each patient with relapsed SCLC
|
Jan 19, 2023 |
|
MDT perspectives on managing side effects associated with second-line treatment for SCLC
|
Jan 19, 2023 |
|
MDT perspectives on tailoring second-line treatment selection to each patient with relapsed SCLC
|
Jan 19, 2023 |
|
MDT perspectives on the current and emerging second-line treatment options for SCLC
|
Jan 19, 2023 |
|
A patient’s perspective: Best practice for shared decision making in the prevention and treatment of migraine
|
Jan 10, 2023 |
|
Optimizing outcomes for patients with Alzheimer’s disease: A focus on transdermal therapy
|
Jan 10, 2023 |
|
What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?
|
Dec 13, 2022 |
|
Improving outcomes in severe paediatric asthma: Insights from a specialist and a PCP
|
Dec 12, 2022 |
|
Improving outcomes in severe paediatric asthma: Insights from a specialist and a PCP
|
Dec 12, 2022 |
|
Tackling unmet needs in chronic myeloid leukemia What’s next in the treatment algorithm
|
Dec 08, 2022 |
|
MDT perspectives on preventing or delaying TSC-associated seizures
|
Dec 08, 2022 |
|
MDT and patient caregiver perspectives on emerging agents for TSC-associated seizures
|
Dec 08, 2022 |
|
MDT and patient caregiver perspectives on the treatment options for TSC-associated seizures
|
Dec 08, 2022 |
|
Prurigo nodularis: Improving awareness, diagnosis, management and quality of life
|
Dec 08, 2022 |
|
Achieving best practice management of primary biliary cholangitis now and in the future
|
Dec 07, 2022 |
|
Achieving best practice management of primary biliary cholangitis now and in the future
|
Dec 07, 2022 |
|
Scanning the horizon of pharmacological treatments for women experiencing vasomotor symptoms during menopause What’s new in 2022
|
Dec 06, 2022 |
|
PARP inhibitors as first-line maintenance therapy in ovarian cancer: How can data from ESGO 2022 guide clinical practice?
|
Nov 30, 2022 |
|
Experts in NTM-LD discuss optimizing the management of patients with NTM-LD to improve outcomes
|
Nov 29, 2022 |
|
Experts in NTM-LD discuss optimizing the management of patients with NTM-LD to improve outcomes
|
Nov 29, 2022 |
|
MDT and patient perspectives on risk factors for stroke in T2D
|
Nov 17, 2022 |
|
MDT and patient perspectives on risk factors for stroke in T2D
|
Nov 17, 2022 |
|
MDT perspectives on guidelines for stroke prevention in T2D
|
Nov 17, 2022 |
|
MDT perspectives on guidelines for stroke prevention in T2D
|
Nov 17, 2022 |
|
MDT and patient perspectives on the MDT’s role in stroke management
|
Nov 17, 2022 |
|
MDT and patient perspectives on the MDT’s role in stroke management
|
Nov 17, 2022 |
|
MDT perspectives on how GLP-1 RAs can reduce stroke risk
|
Nov 17, 2022 |
|
MDT perspectives on how GLP-1 RAs can reduce stroke risk
|
Nov 17, 2022 |
|
Immunogenicity of immune checkpoint inhibitors: Implications for clinical practice
|
Nov 15, 2022 |
|
MDT and patient perspectives on recognizing and referring patients with PNH
|
Nov 14, 2022 |
|
MDT perspectives on managing patients with complement inhibitors
|
Nov 14, 2022 |
|
MDT and patient perspectives on the patient journey in PNH
|
Nov 14, 2022 |
|
Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy
|
Nov 03, 2022 |
|
MDT perspectives on the pathophysiology and comorbidities of non-CF bronchiectasis touchRESPIRATORY
|
Oct 25, 2022 |
|
MDT and patient perspectives on the clinical presentation of non-CF bronchiectasis touchRESPIRATORY
|
Oct 25, 2022 |
|
MDT and patient perspectives on the diagnostic tools for non-CF bronchiectasis
|
Oct 25, 2022 |
|
MDT perspectives on the pathophysiology and comorbidities of non-CF bronchiectasis
|
Oct 25, 2022 |
|
MDT and patient perspectives on the clinical presentation of non-CF bronchiectasis
|
Oct 25, 2022 |
|
MDT and patient perspectives on the diagnostic tools for non-CF bronchiectasis
|
Oct 25, 2022 |
|
Experts discuss latest guidelines and how novel treatments can reduce ASCVD risk in patients with dyslipidemias
|
Oct 11, 2022 |
|
Experts in endocrinology and in primary care discuss addressing cardiorenal outcomes in CKD and T2D
|
Oct 11, 2022 |
|
Experts in endocrinology and in primary care discuss addressing cardiorenal outcomes in CKD and T2D
|
Oct 11, 2022 |
|
Getting personal: Individualizing therapy for cold agglutinin disease
|
Oct 10, 2022 |
|
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
|
Oct 05, 2022 |
|
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
|
Oct 05, 2022 |
|
Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022
|
Oct 03, 2022 |
|
Managing MS in patients over their lifetime
|
Sep 29, 2022 |
|
Imaging disease progression in MS
|
Sep 29, 2022 |
|
Considering the needs and preferences of patients at each treatment decision-making moment
|
Sep 29, 2022 |
|
Navigating the evolving treatment landscape in mTNBC: What are the key considerations for clinical practice today?
|
Sep 28, 2022 |
|
Managing disease progression: Considerations for treatment selection and sequencing
|
Sep 27, 2022 |
|
Mapping an individualized treatment plan: What role does the MDT play?
|
Sep 27, 2022 |
|
Supporting treatment adherence: What strategies are needed for safety management?
|
Sep 27, 2022 |
|
Achieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?
|
Sep 27, 2022 |
|
Managing disease progression: Considerations for treatment selection and sequencing
|
Sep 27, 2022 |
|
Supporting treatment adherence: What strategies are needed for safety management?
|
Sep 27, 2022 |
|
Mapping an individualized treatment plan: What role does the MDT play?
|
Sep 27, 2022 |
|
Achieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?
|
Sep 27, 2022 |
|
Managing disease progression: Considerations for treatment selection and sequencing
|
Sep 27, 2022 |
|
Supporting treatment adherence: What strategies are needed for safety management?
|
Sep 27, 2022 |
|
Mapping an individualized treatment plan: What role does the MDT play?
|
Sep 27, 2022 |
|
Achieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?
|
Sep 27, 2022 |
|
Understanding alopecia areata: Current perspectives and emerging therapies for a complex disease
|
Sep 20, 2022 |
|
Advancing the management of MDS and AML: Novel immune-based approaches
|
Sep 12, 2022 |
|
Experts in cytomegalovirus in solid organ transplants discuss management strategies and emerging therapeutic options
|
Sep 05, 2022 |
|
Experts in cytomegalovirus in solid organ transplants discuss management strategies and emerging therapeutic options
|
Sep 02, 2022 |
|
What’s new for eosinophilic esophagitis? A case-based discussion of patient care
|
Aug 18, 2022 |
|
What’s new for eosinophilic esophagitis? A case-based discussion of patient care
|
Aug 18, 2022 |
|
Higher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022
|
Aug 16, 2022 |
|
Advances in the first-line treatment of ES-SCLC: From clinical data to daily practice
|
Aug 04, 2022 |
|
Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?
|
Aug 04, 2022 |
|
Improving outcomes for patients with advanced renal cell carcinoma
|
Aug 04, 2022 |
|
Experts in paediatric endocrinology discuss the assessment and treatment of children with achondroplasia
|
Aug 03, 2022 |
|
Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?
|
Jul 26, 2022 |
|
Current and emerging treatments for chronic myeloid leukaemia: What have we learnt from the EHA Hybrid Conference 2022?
|
Jul 20, 2022 |
|
Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer
|
Jul 19, 2022 |
|
The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options
|
Jul 08, 2022 |
|
The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options
|
Jul 08, 2022 |
|
Treatment sequencing and the benefits of DMTs
|
Jun 30, 2022 |
|
Breast cancer specialists discuss risk stratification and novel treatment strategies in high-risk HR+ HER2– early breast cancer
|
Jun 15, 2022 |
|
How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
|
Jun 13, 2022 |
|
Navigating the challenges of treatment provision in recurrent/metastatic HNSCC
|
May 26, 2022 |
|
Managing EoE: What options are emerging for patients? - Conversation 3
|
May 24, 2022 |
|
Symptoms of EoE: What is the burden for patients? - Conversation 2
|
May 24, 2022 |
|
Pathophysiology of EoE: What do we see in patients? - Conversation 1
|
May 24, 2022 |
|
Managing EoE: What options are emerging for patients? - Conversation 3
|
May 24, 2022 |
|
Symptoms of EoE: What is the burden for patients? Conversation 2
|
May 24, 2022 |
|
Pathophysiology of EoE What do we see in patients - Conversation 1
|
May 24, 2022 |
|
Experts discuss current and future best practice for the management of non-cystic fibrosis bronchiectasis
|
May 23, 2022 |
|
Experts discuss current and future best practice for the management of non-cystic fibrosis bronchiectasis
|
May 23, 2022 |
|
MDT perspectives on later-line treatment options for CML
|
May 09, 2022 |
|
MDT perspectives on minimizing TKI-associated toxicities in patients with CML
|
May 09, 2022 |
|
MDT perspectives on maximizing quality of life for patients with CML
|
May 09, 2022 |
|
MDT and patient advocate perspectives on what can be learned from patients with CML
|
May 09, 2022 |
|
Extending the benefit of PARP inhibitors through combinations for advanced prostate cancer - Conversation 3
|
May 05, 2022 |
|
PARP inhibitor combination clinical trials for advanced prostate cancer - Conversation 2
|
May 05, 2022 |
|
Rationale for PARP inhibitor combinations for advanced prostate cancer - Conversation 1
|
May 05, 2022 |
|
ENT experts discuss minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis
|
Apr 27, 2022 |
|
ENT experts discuss minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis
|
Apr 27, 2022 |
|
Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion
|
Apr 27, 2022 |
|
Improving patient outcomes in relapsing MS: Current oral DMTs and emerging therapies
|
Apr 26, 2022 |
|
PARP inhibitors as first-line maintenance therapy in ovarian cancer: Update from SGO 2022
|
Apr 20, 2022 |
|
MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D
|
Apr 14, 2022 |
|
MDT and patient perspectives on the safety of GLP-1 RAs and managing their side effects
|
Apr 14, 2022 |
|
MDT and patient perspectives on the role of GLP-1 RAs in the T2D management pathway
|
Apr 14, 2022 |
|
Improving patient outcomes in moderate-to-severe ulcerative colitis
|
Apr 13, 2022 |
|
AAAAI 2022: Improving outcomes for patients with eosinophilic esophagitis
|
Apr 12, 2022 |
|
AAAAI 2022: Improving outcomes for patients with eosinophilic esophagitis
|
Apr 12, 2022 |
|
Unlocking CSU pathogenesis to shape the future treatment landscape
|
Apr 11, 2022 |
|
Identifying, diagnosing and treating patients with later-onset SMA
|
Apr 06, 2022 |
|
Identifying, diagnosing and treating patients with later-onset SMA
|
Apr 05, 2022 |
|
The relationship between people living with HIV and their multidisciplinary team for optimal adherence to ART
|
Apr 04, 2022 |
|
Long-term ART adherence, comorbidities and quality of life for people living with HIV
|
Apr 04, 2022 |
|
Assessing readiness to initiate ART to maximize adherence
|
Apr 04, 2022 |
|
Overcoming barriers to PrEP to optimize uptake and adherence
|
Apr 04, 2022 |
|
Sharing data to improve outcomes in LACC: What’s on the horizon?
|
Mar 31, 2022 |
|
MDT: Current treatment of LACC: Where are we now?
|
Mar 31, 2022 |
|
MDT: Optimizing the patient journey in LACC: Can we reduce the burden?
|
Mar 31, 2022 |
|
MDT and patient perspectives on essential elements of successful SDM in EBC
|
Mar 30, 2022 |
|
MDT perspectives on evidence for the effects of SDM on patient outcomes in EBC
|
Mar 30, 2022 |
|
MDT and patient perspectives on overcoming the challenges of implementing SDM in EBC
|
Mar 30, 2022 |
|
MDT: Sharing data to improve outcomes in LACC: What’s on the horizon?
|
Mar 24, 2022 |
|
Considering the complete picture in neuromyelitis optica spectrum disorder
|
Mar 24, 2022 |
|
Considering the complete picture in neuromyelitis optica spectrum disorder
|
Mar 24, 2022 |
|
MDT and patient perspectives on the importance of the MDT in HF management
|
Mar 22, 2022 |
|
MDT and patient perspectives on new and emerging therapies for HFrEF
|
Mar 22, 2022 |
|
MDT perspectives on the latest guideline recommendations for the treatment of HFrEF
|
Mar 22, 2022 |
|
Multidisciplinary care for CSCC
|
Mar 16, 2022 |
|
CSCC treatment: Systemic therapy
|
Mar 16, 2022 |
|
CSCC treatment: Surgery or radiotherapy
|
Mar 16, 2022 |
|
Diagnostic workup in CSCC
|
Mar 16, 2022 |
|
Multidisciplinary care for CSCC
|
Mar 16, 2022 |
|
CSCC treatment: Systemic therapy
|
Mar 16, 2022 |
|
CSCC treatment: Surgery or radiotherapy
|
Mar 16, 2022 |
|
Diagnostic workup in CSCC
|
Mar 16, 2022 |
|
Multidisciplinary care and quality of life of adolescents/adults with SMA
|
Mar 16, 2022 |
|
Support structures for adolescents with SMA transitioning to the adult healthcare system
|
Mar 16, 2022 |
|
Later-onset SMA: Presentation and differential diagnosis
|
Mar 16, 2022 |
|
Multidisciplinary care and quality of life of adolescents/adults with SMA
|
Mar 16, 2022 |
|
Support structures for adolescents with SMA transitioning to the adult healthcare system
|
Mar 16, 2022 |
|
Later-onset SMA: Presentation and differential diagnosis
|
Mar 16, 2022 |
|
Personalized treatment of RET-altered thyroid cancers
|
Mar 16, 2022 |
|
Personalized treatment of RET-altered thyroid cancers
|
Mar 16, 2022 |
|
Focus on cognitive impairment in the diagnosis and management of relapsing MS – Part 3
|
Mar 15, 2022 |
|
Focus on cognitive impairment in the diagnosis and management of relapsing MS - Part 2
|
Mar 15, 2022 |
|
Focus on cognitive impairment in the diagnosis and management of relapsing MS - Part 1
|
Mar 15, 2022 |
|
MDT and patient perspectives on the importance of treatment intensification, weight loss, and education in T2D and obesity
|
Mar 11, 2022 |
|
MDT and patient perspectives on GLP-1 RA therapy and emerging incretin-based dual agonists in T2D and obesity
|
Mar 11, 2022 |
|
MDT perspectives on the role of incretin hormones in wellness and in T2D
|
Mar 11, 2022 |
|
Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice
|
Mar 09, 2022 |
|
The evolving role of antibody–drug conjugates in the treatment of urothelial carcinoma
|
Jan 31, 2022 |
|
MDT and patient perspectives on the long-term management of patients with severe type 2 asthma
|
Jan 26, 2022 |
|
MDT and patient perspectives on the disease burden of severe asthma
|
Jan 26, 2022 |
|
MDT perspectives on biologic treatment selection in severe type 2 asthm
|
Jan 26, 2022 |
|
MDT and patient perspectives on the disease burden of severe asthma
|
Jan 26, 2022 |
|
MDT perspectives on biologic treatment selection in severe type 2 asthma
|
Jan 26, 2022 |
|
Advancing the treatment of MDS and AML: An update from ASH 2021
|
Jan 24, 2022 |
|
Immunotherapy for recurrent or metastatic head and neck squamous cell carcinoma
|
Jan 24, 2022 |
|
HPV infection and TGF-β: Translating the science into treatments for HPV-associated cancers
|
Jan 20, 2022 |
|
MDT and patient perspectives on the long-term management of patients with severe type 2 asthma
|
Jan 14, 2022 |
|
Immune checkpoint inhibitors in prostate cancer: Current and future practice
|
Jan 13, 2022 |
|
Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice
|
Dec 06, 2021 |
|
Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchIMMUNOLOGY
|
Dec 03, 2021 |
|
Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchRESPIRATORY
|
Dec 03, 2021 |
|
Improving outcomes for patients with NTM-LD
|
Nov 30, 2021 |
|
Improving outcomes for patients with NTM-LD
|
Nov 30, 2021 |
|
Achieving sustained outcomes for moderate-to-severe atopic dermatitis
|
Nov 30, 2021 |
|
Perspectives on the latest clinical data for targeted therapies for thyroid cancer
|
Nov 30, 2021 |
|
Perspectives on biomarker testing and its influence on outcomes in patients with thyroid cancer
|
Nov 30, 2021 |
|
An overview of thyroid cancers from a MDT of experts
|
Nov 30, 2021 |
|
Expert opinions on the management of EDS due to OSA or narcolepsy
|
Nov 29, 2021 |
|
Expert opinions on the management of EDS due to OSA or narcolepsy
|
Nov 29, 2021 |
|
Evolving Standards Of Patient Care in Hepatocellular carcinoma 3
|
Nov 29, 2021 |
|
Evolving Standards Of Patient Care in Hepatocellular carcinoma 2
|
Nov 29, 2021 |
|
Evolving Standards Of Patient Care in Hepatocellular carcinoma
|
Nov 29, 2021 |
|
Choosing IOLs for patients with cataracts: Insights from an expert
|
Nov 25, 2021 |
|
Experts discuss the latest data for emerging HER2-directed therapies in advanced breast cancer
|
Nov 10, 2021 |
|
Making the case for the MDT in NSCLC
|
Nov 10, 2021 |
|
The role of biomarker testing in NSCLC
|
Nov 10, 2021 |
|
Navigating treatment decisions in NSCLC
|
Nov 10, 2021 |
|
Initial assessment of NSCLC
|
Nov 10, 2021 |
|
Experts discuss the emerging role of SERDs in HR+ breast cancer
|
Nov 05, 2021 |
|
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
|
Oct 26, 2021 |
|
Experts discuss non-steroidal MRAs for the treatment of patients with T2D and CKD
|
Oct 25, 2021 |
|
Immunotherapy and evolving approaches for basal cell carcinoma
|
Oct 18, 2021 |
|
Perspectives on the mechanism linking obesity with T2D
|
Oct 13, 2021 |
|
MDT and patient perspectives on antihyperglycemic therapies and their association with weight loss
|
Oct 13, 2021 |
|
MDT and patient perspectives on real-world use of antihyperglycemic therapies to manage T2D and obesity
|
Oct 13, 2021 |
|
Frontline IO for advanced NSCLC: Updates from ASCO and ESMO 2021
|
Oct 06, 2021 |
|
Frontline IO for advanced NSCLC: Updates from ASCO and ESMO 2021
|
Oct 06, 2021 |
|
Type 2 diabetes experts discuss achieving individualized glycemic targets in patients with T2D
|
Sep 30, 2021 |
|
Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 3
|
Sep 23, 2021 |
|
Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 2
|
Sep 23, 2021 |
|
Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 1
|
Sep 23, 2021 |
|
Immunotherapy and evolving approaches for basal cell carcinoma
|
Sep 17, 2021 |
|
Immunotherapy and evolving approaches for basal cell carcinoma
|
Sep 17, 2021 |
|
What is the long-term picture for patients with EGFR-mutant NSCLC?
|
Sep 15, 2021 |
|
What are the implications of adjuvant therapy data on biomarker evaluation?
|
Sep 15, 2021 |
|
How is the advent of adjuvant therapy in NSCLC changing our approach to surgery?
|
Sep 15, 2021 |
|
Patient education, evidence-based treatment and biomarkers in HFrEF
|
Jul 29, 2021 |
|
Highlights from EHA2021 Virtual 2021: Focus on MDS and AML
|
Jul 20, 2021 |
|
Perspectives on the risk factors for ASCVD and guidelines for dyslipidaemia management
|
Jul 20, 2021 |
|
Perspectives on how novel lipid-lowering therapies may help address current unmet needs
|
Jul 20, 2021 |
|
Perspectives on the latest data for novel lipid-lowering therapies
|
Jul 20, 2021 |
|
Perspectives on the risk factors for ASCVD and guidelines for dyslipidaemia management
|
Jul 20, 2021 |
|
Perspectives on how novel lipid-lowering therapies may help address current unmet needs
|
Jul 20, 2021 |
|
Perspectives on the latest data for novel lipid-lowering therapies
|
Jul 20, 2021 |
|
HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?
|
Jun 30, 2021 |
|
Paving the way for optimal disease control in moderate-to-severe type 2 asthma
|
Apr 26, 2021 |
|
Paving the way for optimal disease control in moderate-to-severe type 2 asthma
|
Apr 22, 2021 |
|
ACR 2020 – Predictors of Response in Nr‑axSpA Treated with Certolizumab Pegol: The C-axSpAnd Study
|
Mar 17, 2021 |
|
MAb biosimilars for solid tumours: Perspectives for pharmacists
|
Mar 09, 2021 |
|
Highlights from SABCS 2020 Virtual
|
Jan 18, 2021 |
|
Highlights from ESMO 2020 Virtual
|
Jan 14, 2021 |